The 10-biomarker signature in this category additionally incorporating FABP5, C1RL, MMP9, ECM1, S100A7 and CF1, discriminated early-stage cancers from controls with an AUC of 0.92 (0.86–0.97) (Fig. 3d and Table S2). This evidence concerns the gene MMP9 and cancer.